ABBOTT VASCULAR-CARDIAC THERAPIES
Manufacturer adverse-event records for ABBOTT VASCULAR-CARDIAC THERAPIES come from the U.S. Food & Drug Administration (FDA) MAUDE database via openFDA, refreshed March 2026 - see our methodology. Not medical advice.
FDA MAUDE device safety record · 2004–2014 · thin-book · elevated Death-code · injury-heavy
Death-code intensity
ABBOTT VASCULAR-CARDIAC THERAPIES carries an elevated Death-code share
Death-coded event_type rows are 471 of 6,221 (7.57% · elevated tercile among 443 manufacturers). Absolute volume is thin-book.
What the Death-code reading shows for ABBOTT VASCULAR-CARDIAC THERAPIES
The standout signal for ABBOTT VASCULAR-CARDIAC THERAPIES is Death-code intensity: 7.57% of 6,221 reports (elevated tercile), while absolute volume is thin-book.
As a thinner-book manufacturer, a handful of device families can swing the totals; open the device table rather than reading the company headline alone. Event_type counts are not the same population as Patient Outcomes.
Reports span 17 device types, led in this extract by Injury at 3,468 (55.7% of event_type total). Peak single-year volume reaches 2,439 reports across 6 years. These are raw FDA submissions, not adjudicated findings. Snapshot . Verify current communications on the FDA MDR page.
Event Types
Patient Outcomes
FDA patient-outcome codes (separate from event_type). Percentages use this chart's row total.
Devices (17)
Yearly Trend
Read our methodology - how this data is sourced, computed, and verified.